Erratum: Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form (Cancer Chemotherapy and Pharmacology DOI: 10.1007/s00280-008-0849-9);Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 1, 2009, Pages 87-94

  Shin, Beom Soo ^a   Kim, Hyoung Jun ^b   Hong, Seok Hyun ^b   Lee, Jong Bong ^b   Hwang, Sang Wook ^b   Lee, Mann Hyung ^a   Yoo, Sun Dong ^b  

^a Catholic University of Daegu   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Absorption; DHP 107; Distribution; Paclitaxel

Indexed keywords

DHP 107; PACLITAXEL; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LARGE INTESTINE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OVARY; PRIORITY JOURNAL; SMALL INTESTINE; STOMACH; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADHESIVENESS; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCIPIENTS; FEMALE; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; LIPIDS; MICE; MICE, INBRED ICR; PACLITAXEL; TISSUE DISTRIBUTION;

EID: 67349101641     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0952-6     Document Type: Erratum

References (29)

1. FA Holmes RS Walters RL Theriault AD Forman LK Newton MN Raber AU Buzdar DK Frye GN Hortobagyi 1991 Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer J Natl Cancer Inst 83 1797 1805
2. WK Murphy FV Fossella RJ Winn DM Shin HE Hynes HM Gross E Davilla J Leimert H Dhingra MN Raber 1993 Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer J Natl Cancer Inst 85 384 388 (Pubitemid 23073156)
3. PB Schiff SB Horwitz 1980 Taxol stabilizes microtubules in mouse fibroblast cells Proc Natl Acad Sci USA 77 1561 1565 (Pubitemid 10073801)
4. EK Rowinsky LA Cazenave RC Donehower 1990 Taxol: a novel investigational antimicrotubule agent J Natl Cancer Inst 82 1247 1259 (Pubitemid 20239995)
5. TM Mekhail M Markman 2002 Paclitaxel in cancer therapy Expert Opin Pharmacother 3 755 766 (Pubitemid 34649705)
6. RB Weiss RC Donehower PH Wiernik T Ohnuma RJ Gralla DL Trump JR Baker Jr DA Van Echo DD Von Hoff B Leyland-Jones 1990 Hypersensitivity reactions from Taxol J Clin Oncol 8 1263 1268 (Pubitemid 20195638)
7. A Sparreboom O van Tellingen WJ Nooijen JH Beijnen 1996 Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL Cancer Res 56 2112 2115 (Pubitemid 26119912)
8. H Gelderblom J Verweij K Nooter A Sparreboom 2001 Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur J Cancer 37 1590 1598 (Pubitemid 32778603)
9. TY Kim DW Kim JY Chung SG Shin SC Kim DS Heo NK Kim YJ Bang 2004 Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies Clin Cancer Res 10 3708 3716 (Pubitemid 38697604)
10. A Sparreboom CD Scripture V Trieu PJ Williams T De A Yang B Beals WD Figg M Hawkins N Desai 2005 Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin Cancer Res 11 4136 4143 (Pubitemid 40791578)
11. DW Kim SY Kim HK Kim SW Kim SW Shin JS Kim K Park MY Lee DS Heo 2007 Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann Oncol 18 2009 2014 (Pubitemid 350286241)
12. JL Eiseman ND Eddington J Leslie C MacAuley DL Sentz M Zuhowski JM Kujawa D Young MJ Egorin 1994 Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice Cancer Chemother Pharmacol 34 465 471
13. VJ Wacher L Salphati LZ Benet 2001 Active secretion and enterocytic drug metabolism barriers to drug absorption Adv Drug Deliv Rev 46 89 102
14. A Sparreboom J van Asperen U Mayer AH Schinkel JW Smit DK Meijer P Borst WJ Nooijen JH Beijnen O van Tellingen 1997 Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc Natl Acad Sci USA 94 2031 2035 (Pubitemid 27113956)
15. P Gao BD Rush WP Pfund T Huang JM Bauer W Morozowich MS Kuo MJ Hageman 2003 Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability J Pharm Sci 92 2386 2398 (Pubitemid 37484765)
16. JS Woo CH Lee CK Shim SJ Hwang 2003 Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031 Pharm Res 20 24 30 (Pubitemid 36152913)
17. S Yang RN Gursoy G Lambert S Benita 2004 Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors Pharm Res 21 261 270 (Pubitemid 38221971)
18. SB Tiwari MM Amiji 2006 Improved oral delivery of paclitaxel following administration in nanoemulsion formulations J Nanosci Nanotechnol 6 3215 3221 (Pubitemid 44580003)
19. S Khandavilli R Panchagnula 2007 Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats J Invest Dermatol 127 154 162 (Pubitemid 46005673)
20. S Peltier JM Oger F Lagarce W Couet JP Benoît 2006 Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules Pharm Res 23 1243 1250 (Pubitemid 43946146)
21. X Zhang HM Burt D Von Hoff D Dexter G Mangold D Degen AM Oktaba WL Hunter 1997 An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel Cancer Chemother Pharmacol 40 81 86 (Pubitemid 27160966)
22. C Zhang G Qu Y Sun X Wu Z Yao Q Guo Q Ding S Yuan Z Shen Q Ping H Zhou 2008 Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel Biomaterials 29 1233 1241
23. JW Hong IH Lee YH Kwak YT Park HC Sung IC Kwon H Chung 2007 Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation Mol Cancer Ther 6 3239 3247
24. J van Asperen O van Tellingen A Sparreboom AH Schinkel P Borst WJ Nooijen JH Beijnen 1997 Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833 Br J Cancer 76 1181 1183 (Pubitemid 27448014)
25. HA Bardelmeijer M Ouwehand JH Beijnen JH Schellens O van Tellingen 2004 Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice Invest New Drugs 22 219 229 (Pubitemid 39012561)
26. MV Varma R Panchagnula 2005 Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo Eur J Pharm Sci 25 445 453 (Pubitemid 40853872)
27. L Gianni CM Kearns A Giani G Capri L Viganó A Lacatelli G Bonadonna MJ Egorin 1995 Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans J Clin Oncol 13 180 190
28. JM Gallo S Li P Guo K Reed J Ma 2003 The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice Cancer Res 63 5114 5117 (Pubitemid 37022652)
29. PY Ho TK Yeh HT Yao HL Lin HY Wu YK Lo YW Chang TH Chiang SHW Wu YS Chao CT Chen 2008 Enhanced oral bioavailability of paclitaxel by D-α-tocopheryl polyethylene glycol 400 succinate in mice Int J Pharm 359 174 181